Loss of tumorigenicity and increased immunogenicity induced by interleukin-10 gene transfer in B16 melanoma cells

Human Gene Therapy

Volumn 7, Issue 1, 1996, Pages 23-31

  Gérard, Catherine M ^a   Bruyns, Catherine ^a   Delvaux, Anne ^a   Baudson, Nathalie ^a   Dargent, Jean Louis ^b   Goldman, Michel ^b   Velu, Thierry ^a,b  

^a FREE UNIVERSITY OF BRUSSELS   (Belgium)

^b ERASME HOSPITAL   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

COMPLEMENTARY DNA; INTERLEUKIN 10;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CARCINOGENICITY; CELL DEATH; CONTROLLED STUDY; EXPRESSION VECTOR; GENE TRANSFER; IMMUNE RESPONSE; IMMUNOGENICITY; IMMUNOSTIMULATION; INFLAMMATORY CELL; MELANOMA B16; MOUSE; NATURAL KILLER CELL; NONHUMAN; RETROVIRUS; T LYMPHOCYTE;

EID: 0029921209     PISSN: 10430342     EISSN: None     Source Type: Journal    
DOI: 10.1089/hum.1996.7.1-23     Document Type: Article

References (44)

1. BOTTAZZI, B., WALTER, S., GOVONI, D., COLOTTA, F., and MANTOVANI A. (1992). Monocyte chemotactic cytokine gene transfer modulates macrophage infiltration, growth and susceptibility to IL2 therapy of a murine melanoma. J. Immunol. 148, 1280-1285.
2. BRUYNS, C., GERARD, C., and VELU, T. (1994). Cancer escape from immunosurveillance: How can it be overcome by gene transfer. Eur. J. Cancer 30A, 1176-1181.
3. BURNSTEIN, P., and BRODY, N.I. (1993). Suppression of the delayed type hypersensitivity response by tumor facilitating factor of B16 melanoma. J. Dermatol. Surg. Oncol. 19, 543-552.
4. CHAPMAN, P.B., and HOUGHTON, A.N. (1993). Non-antibody immunotherapy of cancer. Curr. Opin. Immunol. 5, 726-731.
5. CHEN, W.F., and ZLOTNIK, A. (1991). IL10, a novel cytotoxic T cell differentiation factor. J. Immunol. 147, 528-534.
6. CHEN, Q., DANIEL, V., MAHER, D.W., and HERSEY, P. (1994). Production of IL10 by melanoma cells: examination of its role in immunosuppression mediated by melanoma. Int. J. Cancer 56, 755-760.
7. COLOMBO, M.P., and FORNI, G. (1994). Cytokine gene transfer in tumor inhibition and tumor therapy: where are we now? Immunol. Today 15, 48-51.
8. DELVAUX, A., DONCKIER, V., BRUYNS, C., FLORQUIN, S., GERARD, C., AMRAOUI, Z., ABRAMOWICZ, D., GOLDMAN, M., and VELU, T. (1994). Effects of systemic administration of rIL10 in an in vivo model of alloreactivity. Transplantation 58, 972-974.
9. DIALYNAS, D.P., QUAN, Z.S., WALL, K.A., PIERRES, A., QUINTANS, J., LOKEN, M.R., PIERRES, M., and FITCH, F.W. (1983). Characterization of the murine T cell molecule, designated L3T4, identified by monoclonal antibody GK1.5: similarity of L3T4 to human Leu3/T4 molecule. J. Immunol. 131, 2445-2451.
10. DRANOFF, G., JAFFEE, E., LAZENBY, A., GOLUMBEK, P., LEVITSKY, H., BROSE, K., JACKSON, V., HAMADA, H., PARDOLL, D., and MULLIGAN, R.C. (1993). Vaccination with irradiated tumor cells engineered to secrete murine GM-CSF stimulates potent, specific and long-lasting anti-tumor immunity. Proc. Natl. Acad. Sci. USA 90, 3539-3543.
11. FILGUEIRA, L., ZUBER, M., MERLO, A., CAETANO, V., SCHULTZ, E., HARDER, G., SPAGNOLI C., and HERBERER, M. (1993). Cytokine gene transcription in renal cell carcinoma. Br. J. Surg. 80, 1322-1325.
12. FU, Y.-X., WATSON, G.A., KASAHARA, M., and LOPEZ, D.M. (1991). The role of tumor-derived cytokines on the immune system of mice bearing a mammary adenocarcinoma: induction of regulatory macrophages in normal mice by the in vivo administration of rGM-CSF. J. Immunol. 146, 783-789.
13. GANSBACHER, B., ZIER, K., DANIELS, B., CRONIN, K., BANNERJI, R., and GILBOA, E. (1990). Interleukin 2 gene transfer into tumor cells abrogates tumorigenicity and induces protective immunity. J. Exp. Med. 172, 1217-1224.
14. GASTL, G.A., ABRAMS, J.S., NANUS, D.M., OOSTERKAMP, R., SILVER, J., LIU, F., CHEN, M., ALBINO, A.P., and BANDER, N.H. (1993). Interleukin 10 production by human carcinoma cell lines and its relationship to interleukin-6 expression. Int. J. Cancer 55, 96-101.
15. GERARD, C., BRUYNS, C., MARCHANT, A., ABRAMOWICZ, D., VANDENABEELE, P., DELVAUX, A., FIERS, W., GOLDMAN, M., and VELU, T. (1993). IL10 reduces the release of TNF and prevents lethality in experimental endotoxemia. J. Exp. Med. 177, 547-550.
16. GOLSTEIN, P., GORIDIS, C., SCHMITT-VERHULST, A.-M., HAYOT, B., PIERRES, A., VAN AGTHOVEN, A., KAUFMANN, Y., ESHHAR, Z., and PIERRES, M. (1982). Lymphoid cell surface interaction structures detected using cytolysis-inhibiting monoclonal antibodies. Immunol. Res. 68, 5-42.
17. GOTLIEB, W., ABRAMS, J.S., WATSON, J.M., VELU, T.J., BEREK, W.H., and MARTINEZ MAZA, O. (1992). Presence of IL10 in the ascites of patients with ovarian and other intra-abdominal cancers. Cytokines 4, 385-390.
18. HOCK, H., DORSCH, M., KUNZENDORF, U., QIN, Z., DIAMANTSTEIN, T., and BLANKENSTEIN, T. (1993). Mechanisms of rejection induced by tumor cell-targeted gene transfer of IL2, IL4, IL7, TNFα or IFNγ. Proc. Natl. Acad. Sci. USA 90, 2774-2778.
19. HUANG, A.Y., GOLUMBEK, P., AHMADZADEH, M., JAFFEE, E., PARDOLL, D., and LEVITSKY, H. (1994). Role of bone marrow-derived cells in presenting MHC class I-restricted tumor antigens. Science 264, 961-965.
20. IOANNIDES, C.G., and WHITESIDE, T.L. (1993). T cell recognition of human tumors: implications for molecular immunotherapy of cancer. Clin. Immunol. Immunopathol. 66, 91-106.
21. + T lymphocyte migration. J. Immunol. 151, 4545-4551.
22. KLEIN, E., and MANTOVANI, A. (1993). Action of natural killer cells and macrophages in cancer. Curr. Opinion Immunol. 5, 714-718.
23. MARKOWITZ, D., GOFF, S., and BANK, A. (1988). A safe packaging line for gene transfer: separating viral genes on two different plasmids. J. Virol. 62, 1120-1124.
24. MATSUDA, M., SALAZAR, F., PETERSSON, M., MASUCCI, G., HANSSON, J., PISA, P., ZHANG, Q.-J., MASUCCI, M.G., and KIESSLING, R. (1994). Interleukin 10 pretreatment protects target cells from tumor- and allo-specific cytotoxic T cells and downregulates HLA class I expression. J. Exp. Med. 180, 2371-2376.
25. MERLO, A., JURETIC, A., ZUBER, M., FILGUEIRA, L., LUSCHER, U., CAETANO, V., ULRICH, J., GRATZL, O., HEBERER, M., and SPAGNOLI, G.C. (1993). Cytokine gene expression in primary brain tumours, metastases and meningiomas suggests specific transcription patterns. Eur. J. Cancer 29A, 2118-2125.
26. MILLER, A.D., and ROSMAN, G.J. (1989). Improved retroviral vectors for gene transfer and expression. Biotechniques 7, 980-990.
27. MOORE, K.W., O'GARRA, A., DE WAAL MALEFYT, R., VIEIRA, P., and MOSMANN, T.R. (1993). Interleukin 10. Annu. Rev. Immunol. 11, 165-190.
28. NABIOULLIN, R., SONE, S., MIZUNO, K., YANO, S., NISHIOKA, Y., HAKU, T., and OGURA, T. (1994). Interleukin-10 is a potent inhibitor of tumor cytotoxicity by human monocytes and alveolar macrophages. J. Leukoc. Biol. 55, 437-442.
29. PISA, P., HALAPI, E., PISA, E.K., GERDIN, E., HISING, C., BUCHT, A., GERDIN, B., and KIESSLING, R. (1992). Selective expression of IL10, IFNγ and GM-CSF in ovarian cancer biopsies Proc. Natl. Acad. Sci. USA 89, 7708-7712.
30. PORGADOR, A., TZEHOVAL, E., KATZ, A., VADAI, E., REVEL, M., FELDMAN, M., and EISENBACH, L. (1992). Interleukin 6 gene transfection into Lewis Lung Carcinoma tumor cells suppresses the malignant phenotype and confers immunotherapeutic competence against parental metastatic cells. Cancer Res. 52, 3679-3686.
31. RICHTER, G., KRÜGER-KRASAGAKES, S., HEIN, G., HÜLS, C., SCHMITT, E., DIAMANTSTEIN, T., and BLANKENSTEIN, T. (1993). IL10 transfected into chinese hamster ovary cells prevents tumor growth and macrophage infiltration. Cancer Res. 53, 4134-4137.
32. SCHREIBER, H. (1993). Tumor immunology. In Fundamental Immunology. W.E. Paul, ed. (Raven Press, New York) pp. 1143-1178.
33. SCOTT, P. (1993). IL-12: initiation cytokine for cell-mediated immunity. Science 260, 496-497.
34. SMITH, D.R., KUNKEL, S.L., BURDICK, M.D., WILKE, C.A., ORRINGER, M.O., WHYTE, R.I., and STRIETER, R.M. (1994). Production of interleukin 10 by human bronchogenic carcinoma. Am. J. Pathol. 145, 18-21.
35. SPAGNOLI, G.C., JURETIC, A., and SCHULTZ-THATER, E. (1993). On the relative role of IL2 and IL10 in the generation of lymphokine killer cell activity. Cell. Immunol. 146, 391-405.
36. SUN, W.H., KREISLE, R.A. PHILLIPS, A.W., and ERSHLER, W.B. (1992). In vivo and in vitro characteristics of IL6 transfected B16 melanoma cells. Cancer Res. 52, 5412-5415.
37. TAKEYAMA, H., WAKAMIYA, N., O'HARA, C., ARTHUR, K., NILOFF, J., KUFE, D., SAKARAI, K., and SPRIGGS, D. (1991). Tumor necrosis factor expression by human ovarian carcinoma in vivo. Cancer Res. 51, 4476-4480.
38. TEPPER, R.I., and MULE, J.J. (1994). Experimental and clinical studies of cytokine gene-modified tumor cells. Hum. Gene Ther. 5, 153-164.
39. TEPPER, R.I., COFFMAN, R.R., and LEDER, P. (1992) An eosinophil-dependent mechanism for the antitumor effect of IL4. Science 257, 548-551.
40. TRINCHIERI, G. (1994). Recognition of a major histocompatibility complex class I antigens by natural killer cells. J. Exp. Med. 180, 417-421.
41. VELU, T.J., BEGUINOT, W.C., VASS, K., ZHANG, I., PASTAN, I., and LOWY, D.R. (1989). Retroviruses expressing different levels of the normal epidermal growth factor receptor: biological properties and new bioassay. J. Cell. Biochem. 39, 153-166.
42. WHITESIDE, T.L., and PARMIANI, G. (1994). Tumor-infiltrating lymphocytes: their phenotypes, functions and clinical use. Cancer Immunol. Immunother. 39, 15-21.
43. WOGENSEN, L., HUANG, X., and SARVETNICK, N. (1993). Leukocyte extravasation into the pancreatic tissue in transgenic mice expressing IL10 in the islets of Langerhans. J. Exp. Med. 178, 175-185.
44. YAMAMURA, M., MADLIN, R., OHMEN, J.D., and MOY, R.L. (1993). Local expression of anti-inflammatory cytokines in cancer. J. Clin. Invest 91, 1005-1010.